NCT04952350

Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT

Atorvastatin in Hospitalized COVID-19 Patients: A Randomized, Double-blinded, Placebo-Controlled, Clinical Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 220 (actual)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of administering atorvastatin 40 mg to hospitalized COVID-19 patients for 28 days on the all-cause 28-day mortality.

Conditions

• Covid19
• SARS-CoV2 Infection
• COVID-19 Pneumonia

Interventions

Type	Name	Description
DRUG	Atorvastatin 40 Mg Oral Tablet	Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
OTHER	Placebo	A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).

Timeline

• Start date: 2021-08-14
• Primary completion: 2021-11-01
• Completion: 2022-04-01
• First posted: 2021-07-07
• Last updated: 2021-10-25

Locations

1 site across 1 country: Egypt